Literature DB >> 21135112

Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.

Houjian Cai1, Ivan Babic, Xiao Wei, Jiaoti Huang, Owen N Witte.   

Abstract

Cellular Src (c-Src) integrates a large number of signal transduction pathways regulating cell division, migration, and other aspects of cell physiology. Mutations of Src kinase have not been described in human prostate cancer, but evidence for increased levels of expression accompanying cancer progression has been reported. We analyzed overexpression of c-Src in naïve mouse prostate epithelium and observed no change in tubule formation frequency or histologic structure. However, when enhanced c-Src expression is coupled with enhanced expression of androgen receptor (AR), it results in a strong activation of Src kinase activity accompanied by activation of the MAPK pathway, and enhanced AR activity. Similar to the pathology induced by constitutively active c-Src(Y529F), the tubules progress to frank carcinoma with invasion and display markers of epithelial-to-mesenchymal transition. These combined results suggest that nonmutated Src kinase may play a more important role in the genesis and progression of prostate cancer than previously appreciated and that epigenetic changes that enhance the level of AR may select for enhanced expression of c-Src with accompanying activation and a strong drive to malignant progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135112      PMCID: PMC3032821          DOI: 10.1158/0008-5472.CAN-10-1605

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  The interplay between Src family kinases and receptor tyrosine kinases.

Authors:  Paul A Bromann; Hasan Korkaya; Sara A Courtneidge
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Cell-specific regulation of androgen receptor phosphorylation in vivo.

Authors:  Samir S Taneja; Susan Ha; Nicole K Swenson; Hong Ying Huang; Peng Lee; Jonathan Melamed; Ellen Shapiro; Michael J Garabedian; Susan K Logan
Journal:  J Biol Chem       Date:  2005-10-06       Impact factor: 5.157

5.  Lack of activating c-SRC mutations at codon 531 in rectal cancer.

Authors:  M Nilbert; E Fernebro
Journal:  Cancer Genet Cytogenet       Date:  2000-08

6.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.

Authors:  Qunying Lei; Jing Jiao; Li Xin; Chun-Ju Chang; Shunyou Wang; Jing Gao; Martin E Gleave; Owen N Witte; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 7.  The hunting of the Src.

Authors:  G S Martin
Journal:  Nat Rev Mol Cell Biol       Date:  2001-06       Impact factor: 94.444

Review 8.  SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

Authors:  Fred Saad; Allan Lipton
Journal:  Cancer Treat Rev       Date:  2009-12-16       Impact factor: 12.111

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Authors:  Sanaz Memarzadeh; Li Xin; David J Mulholland; Alka Mansukhani; Hong Wu; Michael A Teitell; Owen N Witte
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

View more
  60 in total

1.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 3.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

4.  v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Authors:  Xiaoming Ju; Xuanmao Jiao; Adam Ertel; Mathew C Casimiro; Gabriele Di Sante; Shengqiong Deng; Zhiping Li; Agnese Di Rocco; Tingting Zhan; Adam Hawkins; Tanya Stoyanova; Sebastiano Andò; Alessandro Fatatis; Michael P Lisanti; Leonard G Gomella; Lucia R Languino; Richard G Pestell
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

Review 5.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

6.  CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Authors:  Daniela Sicoli; Xuanmao Jiao; Xiaoming Ju; Marco Velasco-Velazquez; Adam Ertel; Sankar Addya; Zhiping Li; Sebastiano Andò; Alessandro Fatatis; Bishnuhari Paudyal; Massimo Cristofanilli; Mathew L Thakur; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2014-12-01       Impact factor: 12.701

Review 7.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

8.  Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.

Authors:  Qianjin Li; Omar Awad Alsaidan; Yongjie Ma; Sungjin Kim; Junchen Liu; Thomas Albers; Kebin Liu; Zanna Beharry; Shaying Zhao; Fen Wang; Iryna Lebedyeva; Houjian Cai
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

9.  Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Authors:  Edwin M Posadas; Rafi S Ahmed; Theodore Karrison; Russell Z Szmulewitz; Peter H O'Donnell; James L Wade; James Shen; Murali Gururajan; Margarit Sievert; Walter M Stadler
Journal:  Prostate       Date:  2015-10-23       Impact factor: 4.104

10.  miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.